Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Gamma or immune

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424850100 - LYMPHOKINE

424850400 - Interferon

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20100074863ANTI-INFECTIVE PYRROLIDINE DERIVATIVES AND ANALOGS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:03-25-2010
20090123422Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-y - A method of treating idiophathic pulmonary fibrosis (IPF), comprising administering aerosolized interferon-γ in a therapeutically effective amount to achieve improved or ameliorated symptoms of IPF.05-14-2009
20090123421ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS - This invention relates to compositions and methods useful for activating LT-β receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-a and multiple subunits of lymphotoxin-β, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-β receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-β receptor which act as lymphotoxin-β receptor activating agents alone or in combination with other lymphotoxin-β receptor activating agents either in the presence or absence of lymphotoxin-a/β complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-β receptor antibodies either alone or in the presence of other lymphotoxin-β receptor activating agents to potentiate tumor cell cytotoxicity.05-14-2009
20090196853METHOD OF TREATING HEPATITIS VIRUS INFECTION WITH A MULTIPHASIC INTERFERON DELIVERY PROFILE - The present invention provides methods of treating hepatitis virus infection. The methods generally involve administering a composition comprising an antiviral agent in a dosing regimen that achieves a multiphasic serum concentration profile of the antiviral agent. The dosing regimen includes dosing events that are less frequent than with currently available hepatitis therapies. The multiphasic antiviral agent serum concentration profile that is achieved using the methods of the invention effects an initial rapid drop in viral titer, followed by a further decrease in viral titer over time, to achieve a sustained viral response.08-06-2009
20110182856INHIBITORS OF SERINE PROTEASES - The present invention relates to compounds of formula (I):07-28-2011
20100158865Inhibitor of endogenous human interferon-gamma - The invention relates to an inhibitor of endogenous human interferon-gamma (hIFN-ϝ) in autoimmune diseases, especially in multiple sclerosis. More precisely, the invention relates to inactivated protein derivatives of the hIFN-ϝ with preserved affinity to the hIFN-ϝ receptor. The derivatives represent genetically modified variants of hIFN-ϝ, where the C-terminal part of the molecule is either deleted or replaced with a polypeptide sequence of another human protein and a recombinant hIFN-ϝ, inactivated by physical or chemical methods.06-24-2010
20090035270COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF alpha - The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and rumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.02-05-2009
20120183499Method of treating pulmonary disease with interferons - A method of treating a pulmonary disease such as, for instance idiopathic pulmonary fibrosis (IPF), mixed connective tissue disease and asthma, comprising administering an aerosolized interferon such as interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) alone or in combination with other therapeutic agents are provided.07-19-2012
20090068142COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION AND SARS - The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological coronavirus infection, that has clinical sequelae. The present invention further provides methods of reducing the risk that an individual will develop SARS. The present invention further provides methods of treating SARS. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a coronavirus infection.03-12-2009
20080305081Novel aminopyrimidine derivatives as PLK1 inhibitors - The present invention relates to a compound represented by Formula [I]:12-11-2008
20090148407Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication - The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.06-11-2009
20120263680Compositions And Methods For Preventing Or Treating Diseases, Conditions, Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix Deposition - The described invention provides compositions and methods for preventing or treating a disease, condition, or pathologic process characterized by aberrant fibroblast proliferation and extracellular matrix deposition in a tissue of a subject. The method includes administering a therapeutic amount of a pharmaceutical composition comprising a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier.10-18-2012
20100111902COMPOSITION FOR TRANSMUCOSAL DELIVERY OF POLYPEPTIDES - The invention described herein provides an oral solid transmucosal dosage form that enhances transmucosal permeation of biologically active polypeptides across oral mucosal tissue and provides relatively rapid efficacious therapeutic onset thereof. Dosage forms prepared according to the invention can enhance transmucosal absorption of polypeptides in therapeutic serum concentrations to the recipient. The invention provides a solid dosage form for oral transmucosal absorption of a biologically active polypeptide, wherein the dosage form comprises a pharmaceutical composition comprising: a therapeutically active polypeptide; a bile salt; and an effervescent excipient component, which can comprise an effervescent couple and optionally a pH adjusting substance. The invention includes a method of administering a biologically active polypeptide, as well as a method of enhancing transmucosal absorption of a biologically active polypeptide.05-06-2010
20090155208Methods and agents for modulating an immune response - This invention is directed to the targeting of proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule and methods of use thereof. Nucleic acids, vectors comprising the same, and compositions for targeting proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule are disclosed as are methods of use thereof for stimulating or enhancing immune responses in a subject.06-18-2009
20100040576Modified Oligonucleotides For The Treatment Of Hepatitis C Infection - The invention relates to compositions and methods related to the treatment of viral infection. In some embodiments, the invention relates to the treatment of hepatitis C viral infection. In further embodiments, the invention relates to methods of administering oligonucleotide compositions for treating viral infections. In still further embodiments, the invention relates to the administration of antiviral agents, corticosteroids and immunomodulatory agents. In additional embodiments, the invention relates to the manipulation of immunostimulatory motifs within the oligonucleotides.02-18-2010
20100330034USE OF BISPECIFIC ANTIBODIES TO REGULATE IMMUNE RESPONSES - The invention relates generally to the field of immunology, in particular, to bispecific antibodies. Methods for designing a bispecific antibody for use in treating diseases relating to the immune system are disclosed. Specific examples relate to bispecific antibodies which recognize an activating receptor and an inhibiting receptor.12-30-2010
20090304628STABILIZED PHARMACEUTICAL FORMULATIONS THAT CONTAIN THE INTERFERONS GAMMA AND ALPHA IN SYNERGISTIC PROPORTIONS - The present invention is related to stable pharmaceutical formulations to be applied by parenteral (liquids or freeze-dried), or topic way (gel, unguent or cream) that contain different quantities of the recombinant interferons gamma and alpha in synergistic proportions for the treatment of pathological events that contemplate the malignant or benign not-physiological growth of cells in tissue or organs.12-10-2009
20090269305NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.10-29-2009
20120225032Dimeric Alpha Interferon PEGylated Site-Specifically Shows Enhanced and Prolonged Efficacy in Vivo - The present invention concerns methods and compositions for PEGylated complexes of defined stoichiometry and structure. Preferably, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and a PEG moiety to an AD sequence, allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. Alternatively, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-α2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.09-06-2012
20130064791Interferon Analogs - The invention relates to the field of medicine. Among others, it relates to biologically active analogs of interferons (IFNs) which show less unwanted side-effects and to the therapeutic uses thereof. Provided is an IFN analog, wherein the moiety mediating binding to its natural receptor is at least functionally disrupted and wherein the analog comprises a signaling moiety capable of mediating intracellular IFN activity, said signaling moiety being provided at its N-terminus, optionally via a linker, with at least one targeting domain capable of binding to a cell surface receptor other than the IFN receptor.03-14-2013
20130064790PEPTIDES WITH THE CAPACITY TO BIND TO INTERLEUKIN-10 (IL-10) - The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.03-14-2013
20090047246NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.02-19-2009
20120114604Combinations for HCV Treatment - The present invention relates to co-administering a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The combination acts by interfering with the life cycle of the hepatitis C virus and is therefore useful as an antiviral therapy. As such, the combination may be used for treating or preventing Hepatitis C infections in patients. The invention also relates to compositions comprising the combination of inhibitors. The invention also relates to kits and pharmaceutical packs comprising a Hepatitis C virus NS3/4A protease inhibitor and a cytochrome P450 monooxygenase inhibitor. The invention also relates to processes for preparing these compositions, combinations, kits, and packs.05-10-2012
20120114603IFN-ALPHA/BETA-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION THROUGH A NOVEL LIGAND-RECEPTOR PAIR: IFN- LIGANDS ENGAGE A NOVEL RECEPTOR IFN-RN (CRF2-12) AND IL-10R2 (CRF2-4) FOR SIGNALING ANDINDUCTION OF BIOLOGICAL ACTIVITIES - A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.05-10-2012
20090010884PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION - The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents.01-08-2009
20110280829Low Molecular Weight Sulphated Polysaccharides as Candidates for Anti-Angiogenic Therapy - Low molecular weight sulphated L-fucose polysaccharide fraction having a molecular weight ranging from 11 to 30 kDa when measured with TEST A, a sulphate content ranging from 10 and 50% w/w relative to the total weight of the fraction, a fucosis content ranging from 30 and 70% w/w relative to the total weight of the fraction, and a polydispersity index ranging from 1 and 2, wherein the fraction is obtainable by free radical depolymerisation of a crude fucan of vegetal origin; process for manufacturing same; pharmaceutical composition and medicament containing same and their use for inhibiting neovascularisation.11-17-2011
20110142800METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS - This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, methods for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.06-16-2011
20090274656HEPATITIS C VIRUS INHIBITORS - Hepatitis C virus inhibitors are disclosed having the general formula:11-05-2009
20100266543LINKED DIBENZIMIDAZOLE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:10-21-2010
20100266541METHODS AND AGENTS FOR MODULATING AN IMMUNE RESPONSE - This invention is directed to the targeting of proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule and methods of use thereof. Nucleic acids, vectors comprising the same, and compositions for targeting proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule are disclosed as are methods of use thereof for stimulating or enhancing immune responses in a subject.10-21-2010
20110286967LONG-ACTING INTERFERONS AND DERIVATIVES THEREOF AND METHODS THEREOF - A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.11-24-2011
20110300104HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:12-08-2011
20110286966Inhibitor of Endogenous Human Interferon-gamma - Modified endogenous human interferon-gamma (hIFN-γ), biologically inactive but preserving binding affinity to the hIFN-γ receptor, has applicability in the treatment of autoimmune diseases, especially multiple sclerosis.11-24-2011
20090291062PROTEIN FORMULATIONS AND METHODS OF MAKING SAME - The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.11-26-2009
20090297475CYSTEINE DIOXYGENASE POLYMORPHISMS - The invention relates to the detection and identification of polymorphisms in cysteine dioxygenase (CDO) for the use of that diagnosis to identify a propensity in a patient towards rheumatoid arthritis and/or to have side effects with a number of drugs, to nucleic acid and isolated proteins encoding the polymorphisms, to assays for CDO activity and for the identification of compounds affecting CDO activity, and additionally to use of interferon-γ optionally in combination with different compounds, to treat rheumatoid arthritis.12-03-2009
20100119479THERAPEUTIC ANTIVIRAL PEPTIDES - Disclosed herein are compounds represented by a formula:05-13-2010
20090087409Viral Polymerase Inhibitors - An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I:04-02-2009
20100098660Method of treating tuberculosis with interferons - A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Further, a method of reducing the infectivity of tuberculosis or reducing the number of infectious organisms present in the lungs of a patient suffering from tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.04-22-2010
20090263354Compositions and siRNAs for inhibiting C/EBPbeta - The invention relates to C/EBPβ and modulation of cell resistance or sensitivity to triggers of cell death. More particular, it provides pharmaceutical compositions and siRNAs for inhibiting C/EBPβ thus decreasing resistance or enhancing sensitivity of cancer cells to a cancer therapy.10-22-2009
20090092582Compositions and methods for modifying properties of biologically active polypeptides - The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.04-09-2009
20090257980ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES - The present invention provides the use of IFN-β, an agent that increases the expression of IFN-β, or a polynucleotide which is capable of expressing IFN-β or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-λ for the same purpose.10-15-2009
20090257979Novel Inhibitors of Hepatitis C Virus Replication - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.10-15-2009
20100124544CRYSTALLINE FORMS OF DIHYDROPYRAZOLOPYRIMIDINONE - The present invention relates to the crystalline forms of 2-allyl-1-[6-(I-hydroxy-1 methylethyl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one or a salt thereof, which are useful in the field of treatment of various cancers as a kinase inhibitor, especially as a Weel kinase inhibitor.05-20-2010
20090142300Compositions and methods related to toll-like receptor-3 - The invention relates to compositions and methods related to Toll-like receptor (TLR) polypeptides. In some embodiments, the invention relates to managing TLR3 related diseases. In further embodiments, the invention relates to methods of preventing and treating inflammation. In some embodiments, the invention relates to antagonists of TLR3, to amino acid sequences that act as dominant negative molecules, and to nucleic acid sequences that encode said amino acid sequences. In additional embodiments, the invention relates to the manipulation of biological materials to evaluate TLR3 activity.06-04-2009
20100226884Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) - The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.09-09-2010
20100135960ANTIVIRAL ACYLSULFONAMIDE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:06-03-2010
20080292585Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom - Azonafide derivatives are obtained by reacting azonafide with aldehydes, acyl halides, thioacyl halides, monoisocyanates, isothiocyanates, sulfonyl halides, monohalogenoalkanes, monohalogenoalkenes or monohalogenoalkynes, and are useful as active ingredients of pharmaceutical compositions for the prevention and treatment of cell proliferative disorders, in particular several forms of Cancer.11-27-2008
20080213216Methods of stimulating phagocytosis - The present invention relates, in general, to methods of stimulating phagocytosis and thereby combating infection and/or modulating immune complex disease, in particular, to methods of modulating the number and type of Fc receptors present on cells that normally possess such receptors, including monocytes and macrophages, as well as on cells that normally do not possess Fc receptors, such as fibroblasts, and to compounds and compositions suitable for use in such methods.09-04-2008
20080267915Hcv Ns3-Ns4a Protease Inhibition - The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the invention emply inhibitors that act by interfering with the life cycle of the HCV and are also useful as antiviral agents. The invention further relates to compositions comprising such compounds either for ex vivo use or for administration to a patient suffering from genotype-2 or genotype-3 HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.10-30-2008
20090123420Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase - The present invention provides improved treatment methods by the administration of the non-physiologic D-isomer of an IDO inhibitor.05-14-2009
20110223133THERAPEUTIC AGENT FOR HEMATOPOIETIC TUMORS - An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon α, interferon γ, or the IRF-2 protein as an active ingredient, as well as an antitumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24.09-15-2011
20090162319REVERSE TRANSCRIPTASE INHIBITORS - Described herein are novel enzyme inhibitors. In some embodiments, the enzyme inhibitors are reverse transcriptase inhibitors, particularly HIV reverse transcriptase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition of HIV reverse transcriptase as a method of treating or preventing HIV, AIDS or related disorders.06-25-2009
20120070414Controlling disease vectors from insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi - The present invention utilizes extracts of the pre-sporulation (preconidial) mycelial stage of entomopathogenic fungi as insect and arthropod attractants and/or pathogens and can be employed to limit the zoonotic and plant diseases they transmit. The fungus can be cultivated on grain, wood, agricultural wastes or other cellulosic material and extracts can be made thereof. More than one fungus and substrate can be used in combination with one or more antimicrobial, antiprotozoal, antiviral, or genetically modified agents that result in reduced spread of contagions and lessens the damage they inflict on animals and plants.03-22-2012
20090022689C4-SPIRO-PYRROLIDINE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:01-22-2009
20090053175SUBSTITUTE PYRROLIDINE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:02-26-2009
200900041404-SUBSTITUTED PYRROLIDINE AS ANTI-INFECTIVES - The present invention discloses compounds of Formulae (I) and (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof:01-01-2009
20110142799MODULATION OF NEURODEGENERATIVE DISEASE BY MODULATING XBP-1 ACTIVITY - The invention provides methods for treating and preventing a neurodegenerative disease associated with aberrant protein aggregation by modulating the expression and/or activity of XBP-1, IRE-1 alpha, and/or EDEM. The present invention also pertains to methods for identifying compounds that modulate the expression and/or activity of XBP-1, 1RE-1 alpha, and/or EDEM. The present invention further provides methods for determining whether a subject is at risk of developing or has developed a neurodegenerative disease associated with aberrant protein aggregation.06-16-2011
20090208452Inhibitor of Endogenous Human Interferon-Gamma - The invention relates to an inhibitor of endogenous human interferon-gamma (hIFN-ϝ) in autoimmune diseases, especially in multiple sclerosis. More precisely, the invention relates to inactivated protein derivatives of the hIFN-ϝ with preserved affinity to the hIFN-ϝ receptor. The derivatives represent genetically modified variants of hIFN-ϝ where the C-terminal part of the molecule is either deleted or replaced with a polypeptide sequence of another human protein and a recombinant hIFN-ϝ inactivated by physical or chemical methods.08-20-2009
20090220456USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE - This invention provides a method for preventing or treating Severe Acute Respiratory Syndrome in a subject comprising administering to the subject an effective amount of recombinant super-compound interferon or a functional equivalent thereof. This invention provides a method for inhibiting the causative agent of Severe Acute Respiratory Syndrome comprising contacting the agent with an effective amount of super-compound interferon or its equivalent.09-03-2009
20090246174TREATMENT FOR CUTANEOUS T CELL LYMPHOMA - The present invention provides method for treating a patient with cutaneous T cell lymphoma (CTCL). Generally, the methods include administering to the patient an IRM compound in an amount effective to ameliorate at least one symptom or clinical sign of CTCL. In some embodiments, the methods also include administering to the patient a priming dose of a Type I interferon. In another aspect, the invention provides methods of increasing a cell-mediated immune response of a cell population that includes cells affected by cutaneous T cell lymphoma. Generally, the methods include contacting the cell population with an IRM compound in an amount effective to increase at least one cell-mediated immune activity of the cell population. In some embodiments, the methods include contacting the cell population with a priming dose of a Type I interferon.10-01-2009
20100254942HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS - The present invention relates to novel compositions having anti-viral activity and in particular it relates to synergistic compositions active against Hepatitis C virus (HCV). The invention also relates to methods for retarding, reducing or otherwise inhibiting HCV growth and/or functional activity.10-07-2010
20100183551Macrocyclic Compounds As Antiviral Agents - A class of macrocyclic compounds of formula (I), wherein R07-22-2010
20090047247Pyrrolidine Derivatives - The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:02-19-2009
20100260715HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:10-14-2010
20100221215LINKED DIBENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:09-02-2010
20100221216HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:09-02-2010
20100221214LINKED DIBENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:09-02-2010
20110059044Method of treating pulmonary disease with interferons - A method of treating a pulmonary disease such as, for instance idiophathic pulmonary fibrosis (IPF) and asthma, comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.03-10-2011
20100226881PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY - Pyrazolo[1,5-a]pyridines are described, including methods for their preparation, and their use as agents or drugs for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.09-09-2010
20090074719Peptides, Peptidomimetics and Small Molecule Inhibitors of the Epstein-Barr Virus Mediated Fusion and Entry Process - Disclosed are compositions and methods for modulating Epstein-Barr virus (EBV) infection in a patient. The compositions may include peptides or peptidomimetics that are related to gp42 and function to inhibit EBV-mediated membrane fusion.03-19-2009
20110236349Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection - The present invention provides methods of treating a viral infection in an individual. The methods generally involve administering to an individual an effective amount of an epidermal growth factor receptor (EGF-R) inhibitor.09-29-2011
20100266542RECEPTOR COUPLING AGENTS AND THERAPEUTIC USES THEREOF - Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.10-21-2010
20090136449Tetracyclic Indole Derivatives as Antiviral Agents - The present invention relates to tetracyclic indole derivatives of formula (I); wherein Ar, D05-28-2009
20110243892Y-SHAPE BRANCHED HYDROPHILIC POLYMER DERIVATIVES, THEIR PREPARATION METHODS, CONJUGATES OF THE DERIVATIVES AND DRUG MOLECULES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE CONJUGATES - The present invention relates to Y-shape branched PEG derivatives of formulae (I) to (IV). The present invention also relates to conjugates of these Y-shape derivatives and drug molecules, pharmaceutical compositions comprising those conjugates.10-06-2011
20100310511DETERMINING DISEASE OR IMMUNE SYSTEM FEATURES BASED ON ANALYSIS OF IMMUNE SYSTEM CHARACTERISTICS - Methods for analyzing one or more elements, markers, ligands or other characteristics of the immune system of a body (e.g., of a human or other animal), and based on the analysis, determine a location of disease, identify immune system failure, and/or determine treatments based on disease location or immune system failure. All or a part of the immune system process may be analyzed to identify specific features of the immune system, e.g., which may indicate that the disease will evade the immune system and produce a negative outcome. Therapy may be employed to correct immune system failure rather than addressing the disease directly.12-09-2010
20110129444NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.06-02-2011
20110110890Novel Inhibitors of Hepatitis C Virus Replication - The embodiments provide compounds of the general Formula I and compound 105S, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.05-12-2011
20110008288HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:01-13-2011
20110243891DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE - The present invention relates to a compound of General Formula (I) below, among others. In the Formula, Ar10-06-2011
20110086006HCV NS3-NS4 Protease Resistance Mutants - The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.04-14-2011
20090324544SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:12-31-2009
20110177027COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha - The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and tumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.07-21-2011
20110177026Use of Alpha-Glucosidase Inhibitors to Treat Alphavirus Infections - The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent.07-21-2011
20110150832FURIN-KNOCKDOWN BI-FUNCTIONAL RNA - Compositions and methods to attenuate the immunosuppressive activity of TGF-β through the use of bi-functional shRNAs is described herein. The bi-functional shRNAs of the present invention knocks down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.06-23-2011
20110081315NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, Ia, II, III, IV, V, VI-1, VI-2, VII, VIII, IX, X, XI, and XII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.04-07-2011
20110070197HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:03-24-2011
20110070196HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:03-24-2011
20110250174STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES - The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterised in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.10-13-2011
20090022688INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds of formula I:01-22-2009
20100003217Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections - Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.01-07-2010
20090297476NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.12-03-2009
20110165121USE OF PEGYLATED TYPE III INTERFERONS FOR THE TREATMENT OF HEPATITIS C - Methods for treating human patients infected with the hepatitis C virus using pegylated Type III Interferons (IL-28A, IL-28B and IL-29) alone or in combination with other antiviral agents.07-07-2011
20100284969Methods and Compositions for Delivery of Medicaments to the Lungs - The disclosure provides a drug composition formulated for inhalation comprising a conjugate of a surface active agent and a pulmonary active drug. The surface active agent has an affinity for the human alveolar/gas interface and comprises at least a portion of a mammalian lung surfactant of a mimic thereof. The disclosure also provides a method of treating a subject suffering from or at risk of suffering from a lung disease comprising administering to the subject a conjugate comprising a drug for lung treatment and a surface active agent by inhalation in an amount effective to induce a drug effect in the lungs.11-11-2010
20110064698HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:03-17-2011
20110135601BICYCLOANILINE DERIVATIVE - The invention relates to a compound of a general formula (I):06-09-2011
20110135602SUPPERSSOR OF THE ENDOGENOUS INTERFERON-GAMMA - The invention relates to suppressor of the endogenous human interferon-gamma (hlFN-γ) applicable in treatment of diseases associated with impaired activity of endogenous hlFN-γ, especially autoimmune diseases and for prevention of graft arteriosclerosis and rejection of organs in allograft transplanted patients. It is based on inactive analogues of the hlFN-γ with pre-served affinity to the hlFN-γ receptor, genetically modified in the domain responsible for triggering the signal transduction pathway.06-09-2011
20110262398CARDIAC TREATMENT USING ANTI-FIBROTIC AGENTS - Disclosed herein are reagents and methods for detecting and treating age-related diastolic dysfunction in an animal or a human.10-27-2011
20120148532Method of treating pulmonary disease with interferons - A method of treating a pulmonary disease such as, for instance idiophathic pulmonary fibrosis (IPF) and asthma, comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.06-14-2012
20090175821Modified therapeutic peptides with extended half-lives in vivo - A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.07-09-2009
20110189129HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:08-04-2011
20110189130DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES - The invention relates to compounds of a general formula (I):08-04-2011
20110033419Methods and Compositions for Treating Cancer - The invention relates to a method of treating cancer, comprising administering to a subject in need thereof an effective amount of a HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10. The invention further relates to pharmaceutical compositions comprising HSV-2 virus, wherein the virus lacks protein kinase activity of ICP10.02-10-2011
20090016990Antimicrobial Compositions - The present invention relates in part to a composition comprising a compound of Formula I or Formula II and at least one other antimicrobial agent. The invention also relates in part to a pharmaceutical composition comprising the composition of claim 01-15-2009
20100272681Inhibitors of Serine Proteases - The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.10-28-2010
20090208453High pressure treatment of aggregated interferons - High pressure to treat aggregated interferons, particularly recombinant human interferon-β, to reduce the aggregate content of interferon material. Highly pure, soluble monomeric recombinant interferon-β is prepared in representative embodiments. Multiple strategies may be used in combination that make nonglycosylated IFN-β more amenable to high pressure treatment. It has been found that refolding yields of high pressure treatment can be significantly improved by use of a combination of strategies, including, or example a pre-treatment of the IFN-β that involves solubilizing and then precipitating the protein. This pre-treatment is particularly effective with respect to recombinant IFN-β inclusion bodies recovered from host cells such as 08-20-2009
20080311078Self-Buffering Protein Formulations - The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use. The invention in these and other respects can be productively applied to a wide variety of proteins and is particularly useful for making and using self-buffering formulations of pharmaceutical proteins for veterinary and medical use, especially, in particular, for the treatment of diseases in human subjects.12-18-2008
20100150867USE OF ALPHA-GLUCOSIDASE INHIBITORS TO TREAT ALPHAVIRUS INFECTIONS - The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent.06-17-2010
20110305667USE OF A DEAD-BOX RNA HELICASE FOR INDUCING CYTOKINE PRODUCTION - The invention relates to the use of a DEAD-box RNA helicase from a yeast, a mammal, 12-15-2011
20090074718Avian derived erythropoietin - Erythropoietin obtained from eggs laid by transgenic avians having avian N-linked and O-linked glycosylation patterns.03-19-2009
20100226883LINKED DIIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:09-09-2010
20090004139INTERFERON-BETA AND/OR LAMBDA FOR USE IN TREATING RHINOVIRUS INFECTION IN THE ELDERLY - Use of interferon-beta (IFN-β) and/or IFN-λ for treating rhinovirus (RV) infection in elderly people, particularly elderly people who are, or have been long-term smokers, especially those who have a clinical history of recurrent RV infections, and may have other medical conditions, such as cardiac or circulation problems, and who are liable to suffer severe complications/high mortality from poor innate ability to fight such a viral infection.01-01-2009
20120039848HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:02-16-2012
20080219950DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS - The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.09-11-2008
20080219951Stabilization of Biologically Active Proteins With Mixtures of Polysaccharides and Amino Acid Based Compounds - The invention provides heat stable aqueous solutions or gels comprising a biologically active protein and a stabilizing effective amount of a mixture of a polysaccharide and an amino acid based compound. The invention also discloses stabilized solutions or gels suitable for use in an implantable drug delivery device at body temperature, and a device containing the stabilized solution or gels.09-11-2008
20110064697HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:03-17-2011
20110171175INHIBITORS OF SERINE PROTEASES - This invention relates to compounds of formula I:07-14-2011
20120045415TREATMENT OF HEPATITIS C VIRUS WITH TELAPREVIR (VX-950) IN PATIENTS NON-RESPONSIVE TO TREATMENT WITH PEGYLATED INTERFERON-ALPHA 2A/2B AND RIBAVIRIN - The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.02-23-2012
20100233122NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:09-16-2010
20120009149Tetrameric Cytokines with Improved Biological Activity - The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-α2b.01-12-2012
20120014914INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASES - The present invention relates to compounds of formula I:01-19-2012
20120058082METHODS AND COMPOSITIONS FOR TREATMENT - The invention provides methods for improving the efficacy and reducing side effects of anti-CD52 antibody treatment. The methods can be used to treat patients who are in need of immunoregulation such as lymphocyte depletion and patients who have cancer. Also included are compositions useful for these methods.03-08-2012
20120058081Ex-vivo treatment of peripheral blood leukocytes with IFN-lambda - The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-λ). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-λ and returned to the patient. The present invention also provides a method of ex vivo treatment, in conjunction with co-administration of IFN-λ03-08-2012
20110091421Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases - The present invention discloses multiple treatment regimens for vascular-related diseases and disorders. The present invention provides for methods of treating vascular-related disorders based on gene expression studies from samples collected from individuals having symptoms of vascular-related disorders. Additionally, methods are disclosed involving diagnostic techniques to focus treatment regimens. Finally, methods of treating vascular-related disorder involving targeting microRNAs are also disclosed.04-21-2011
20090142301NOVEL PHARMACEUTICAL COMPOSITION OF INTERFERON GAMMA OR PIRFENIDONE WITH MOLECULAR DIAGNOSTICS FOR THE IMPROVED TREATMENT OF INTERSTITIAL LUNG DISEASES - The present invention relates to a novel pharmaceutical composition of compounds having the biological activity of interferon gamma (IFN-γ) or pirfenidone in combination with a diagnostic array of candidate polynucleotides for the improved treatment of all forms of interstitial lung disease, in particular of idiopathic pulmonary fibrosis (IPF).06-04-2009
20110104115INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.05-05-2011
20120251493NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.10-04-2012
20120164104Composition and Methods of Treating Viral Infections and Viral Induced Tumors - The present invention provides methods of treating viral induced tumor or viral infections, including administering a compound described in the invention in a therapeutically effective amount. According to some aspect of the present invention, the methods may further comprise at least one immunosuppressant agent to treat viral infection and/or viral induced tumor to a subject in need of immunosuppressant agents.06-28-2012
20100226882LINKED DIIMIDAZOLE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:09-09-2010
20100209391NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments also provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.08-19-2010
20110182857Delivery of Drugs to Mucosal Surfaces - Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.07-28-2011
20120213734Method for Cancer Therapy Based on a Co-Administration of a Parvovirus and a Cytokine - Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a cytokine, preferably IFN-γ, and the use of said composition for treatment of cancer, e.g., a brain tumor.08-23-2012
20120219523Method of treating tuberculosis with interferons - A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Further, a method of reducing the infectivity of tuberculosis or reducing the number of infectious organisms present in the lungs of a patient suffering from tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided.08-30-2012
20100221217THERAPEUTIC COMPOSITION - Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof.09-02-2010
20120076757COMPOSITION FOR TRANSMUCOSAL DELIVERY OF POLYPEPTIDES - The invention described herein provides an oral solid transmucosal dosage form that enhances transmucosal permeation of biologically active polypeptides across oral mucosal tissue and provides relatively rapid efficacious therapeutic onset thereof. Dosage forms prepared according to the invention can enhance transmucosal absorption of polypeptides in therapeutic serum concentrations to the recipient. The invention provides a solid dosage form for oral transmucosal absorption of a biologically active polypeptide, wherein the dosage form comprises a pharmaceutical composition comprising: a therapeutically active polypeptide; a bile salt; and an effervescent excipient component, which can comprise an effervescent couple and optionally a pH adjusting substance. The invention includes a method of administering a biologically active polypeptide, as well as a method of enhancing transmucosal absorption of a biologically active polypeptide.03-29-2012
20120076756NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:03-29-2012
20120076755Hepatitis C Virus Inhibitors - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:03-29-2012
20100272682METHOD FOR IMPROVING PHARMACOKINETICS - The object of the present invention is to elevate the blood levels of a compound of formula I by co-administration with a cytochrome P450 inhibitor.10-28-2010
20090060872PHOSPHADIAZINE HCV POLYMERASE INHIBITORS V - Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formulas V, V′, I″, II″, or Va, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.03-05-2009
20090208451HALOGEN PHOSPHONATE MONOESTERS - The present invention relates to detection, immobilization, and production of proteolytic antibodies using halogen phosphonate monoester probes, immobilizing reagents, and antigen conjugates.08-20-2009
20110123495DERIVATIVES OF PYRIDONE AND USE THEREOF - The present invention provides N-substituted-2(1H) pyridones or the pharmaceutical acceptable salts thereof, and the pharmaceutical preparations containing the compounds. The compounds of the present invention can be used to treat various fibrotic diseases effectively, e.g., hepatic fibrosis.05-26-2011
20110002884THERAPEUTIC COMPOUNDS - A class of macrocyclic compounds of formula (I), wherein R01-06-2011
20110038834NOVEL AVIAN CYTOKINES AND GENETIC SEQUENCES ENCODING SAME - The present invention relates generally to novel recombinant polypeptides having avian cytokine properties and to genetic sequences encoding same. More particularly, the present invention is directed to recombinant avian Type III interferon polypeptides, and genetic sequences encoding same, together with cellular expression systems and uses for same. Even more particularly, the present invention is directed to avian interferon-λ (IFN-λ) and functional derivatives, homologues and fragments thereof and to methods of use thereof. The molecules and cells of the present invention are useful in a wide range of applications including, but not limited to, providing a means for the treatment and prophylaxis of disease conditions, in particular avian disease conditions, or for use as an immune response modulator. Also provided are diagnostic means for screening for immune response and screening means for identifying modulators of IFN-λ protein or nucleic acid functionality.02-17-2011
20100233123PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS - Provided herein are phosphothiophene and phosphothiazole compounds, for example, of any of Formulae I, IA, IIA, IIIA, IVA, VA, VIA, VIIA, IB, IIB, IIIB, IVB, VB, VIIB and VIIB disclosed herein, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host infected with HCV.09-16-2010
20110250173Methods and compositions for inhibition of Treg cells - The present invention relates to methods of suppressing the immune tolerance of a disease or disease antigens in a patient. The method also promotes the activity of the effector T lymphocytes. The invention includes administering a therapeutic composition that promotes a Th1 environment in the patient while decreasing the immunosuppressive activity of Treg cells that can lead to disease antigen tolerance and immunoavoidance of the disease antigens by the patient. The therapeutic composition includes allogeneic emTh-1 cells. The therapeutic composition can also include disease antigens such as the chaperone-rich cell lysate of the disease antigen.10-13-2011
20090081161Treatment of neoplasms with viruses - The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.03-26-2009
20080226596Therapeutic compositions and methods useful in treating hepatitis - The invention encompasses therapeutic compositions containing a pentavalent antimonial composition. The pentavalent antimonial can be sodium stibogluconate and pentamidine and biological equivalents of said compounds. The therapeutic composition of this embodiment contains an effective amount of pentavalent antimonial that can be used in treating infectious diseases. The types of diseases that can be treated with the present invention include, but are not limited to, the following: diseases associated with PTPase activity, immune deficiency, cancer, infections (such as viral infections), hepatitis B, and hepatitis C. The therapeutic composition enhances cytokine activity. The therapeutic composition may include a cytokine, such as interferon α, interferon β, interferon γ, or granulocyte/macrophage colony stimulating factor. The composition may also include a second agent for treating hepatitis.09-18-2008
20130171104SYNERGISTIC ACTIVITY OF MODULATORS OF THE NO METABOLISM AND OF NADPH OXIDASE IN THE SENSITIZATION OF TUMOR CELLS - What is disclosed is pharmaceutical compositions which contain a pharmaceutically active amount of at least one active substance which increases the available NO concentration in the cell, together with at least one active substance which stimulates the NADPH oxidase.07-04-2013
20110274656PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATITIS C, COMPRISING THE ROOTS EXTRACT OF PLATYCODON GRANDIFLORUM OR PLATYCODON GRANDIFLORUM SAPONIN COMPONENTS - The present invention relates to a pharmaceutical composition for preventing or treating Hepatitis C, comprising the roots extract of 11-10-2011
20110274655TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE - Provided herein are tetrazolone FASN inhibitors of the formula (I):11-10-2011
20110274654TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE - Provided herein are triazole FASN inhibitors of the formula (I):11-10-2011
20110274653DENDRITIC CELL IMMUNORECEPTORS (DCIR)-MEDIATED CROSSPRIMING OF HUMAN CD8+ T CELLS - Immunostimulatory compositions and methods comprising an ITIM motif-containing DC immunoreceptor (DCIR) to mediate potent crosspresentation are described herein. The inventors evaluated human CD8+ T cell responses generated by targeting antigens to dendritic cells (DCs) through various lectin receptors. A single exposure to a low dose of anti-DCIR-antigen conjugate initiated antigen-specific CD8+ T cell immunity by all human DC subsets including ex vivo generated DCs, skin-isolated Langerhans cells and blood mDCs and pDCs. Enhanced specific CD8+ T cell responses were observed when antigens like, FluMP, MART-1, viral (HIV gag), etc. were delivered to the DCs via DCIR, compared to those induced by a free antigen, or antigen conjugated to a control mAb or delivered via DC-SIGN, another lectin receptor. Addition of Toll-like receptor (TLR) 7/8-agonist enhanced DCIR-mediated crosspresentation as well as crosspriming. Thus, antigen targeting via the human DCIR receptor allows activation of specific CD8+ T cell immunity.11-10-2011
20090155209NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.06-18-2009
20100021427Use of Antiviral Peptides For Treatment of Infections Caused by Drug-Resistant HIV - The present invention provides methods of treating drug-resistant HIV infections especially of HIV strains that are resistant to infusion inhibitors, such as T20.01-28-2010
20130101553INDUCING INACTIVATION OF FIBROGENIC MYOFIBROBLASTS - Provided are methods of treating fibrotic conditions in a subject and diagnostic methods for determining fibrosis and appropriate treatments for the fibrosis by the identification of specific subsets of fibrogenic myofibroblasts.04-25-2013
20130129678CO-ADMINISTRATION OF A PARVOVIRUS AND A CYTOKINE FOR THERAPY OF PANCREATIC CANCER - The application relates to a combination of a parvovirus and a cytokine, preferably IFNγ, for use in treating pancreatic cancer (PDAC), in particular a terminal stage of this disease.05-23-2013
20130177531Inhibitors of Serine Proteases - This invention relates to compounds of formula I:07-11-2013
20110250172HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:10-13-2011
20100316607HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:12-16-2010
20130156734Compositions and Methods for Treating Friedreich's Ataxia with Interferon Gamma - Described herein are compositions and methods for treating Friedreich's Ataxia (FRDA) with interferon gamma. In some aspects, methods for increasing expression of frataxin in cells and for treating Friedreich's Ataxia are provided. In some additional aspects, methods increasing aconitase activity in cells are provided.06-20-2013
20130183269Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.07-18-2013
20110305668METHODS FOR USING INTERFERON GAMMA TO ABSORB FLUID FROM THE SUBRETINAL SPACE - Particular aspects of the invention provide methods for decreasing the amount of fluid present in the subretinal space of the eye by administering interferon gamma to the basolateral side of the retinal pigment epithelium. Adverse ocular conditions associated with the accumulation of fluid in the subretinal space can be treated by administering an amount of interferon gamma to the basolateral side of the retinal pigment epithelium effective to remove excess fluid from the subretinal space.12-15-2011
20120034186INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER - Protein tyrosine phosphatase (PTP) Shp2 is a non-receptor PTP that involved in cell signaling and regulation of cell proliferation, differentiation, and migration. Shp2 mediates activation of kinases that are involved in the pathogenesis of human carcinoma. A high throughput screen identified compounds that inhibit the PTP Shp2. Several compounds were identified that selectively inhibit Shp2 over Shp1 with low to sub-micromolar activity. Also disclosed are methods of inhibiting a protein tyrosine phosphatase in a cell and treating cancer through selective inhibition of Shp2.02-09-2012

Patent applications in class Gamma or immune